Health protection – with Nature hand in hand


Our mission statement and our pledge for our users, collaborators and investors:
Biomed Protection is a company dedicated to protect human and animal health. Our efforts are aimed at developing strategies for a longer and healthier life. These goals will be achieved by bringing the basic principles of Nature, established for living organisms during millions of years of the evolution, to the everyday life.

Our goal is:
- to become the first company to fully implement the concept of the long-range molecular interactions in protection and improvement of the human health.

Some of our near-term milestones are:
- to discover new therapeutic targets for infectious diseases and cancer and help develop new generation of drugs and vaccines, which are effective against multi-drug resistant pathogens and cancer cells
- to help people improve their health by adjusting their lifestyle in accord with the basic principles of Nature.

Molecular Sensing (MS) Concept



Molecular descriptors AQVN and EIIP are used to determine the basic physico-chemical properties of nutrients and to establish the first molecular-based recommendations for healthy diet. Based on these results an App which helps in planning of the healthy eating was developed.



Numerous population and clinical studies confirmed protective effect of physical activity against breast and prostate cancer and HIV disease but the molecular mechanisms of this phenomenon remained elusive. The MS-based bioinformatics tool was used for study of modulation of the immune system by physical activity. Possible molecular mechanism underlying protective effect of physical exercise against cancer and HIV disease was proposed (Veljkovic et al. Scand J Med Sci Sports 2-10;20:469, Veljkovic et al. Med Hypotheses 2011;77:404, Veljkovic et al. PLOS One 2011;6:e28304).



Bioinformatics tools based on the MS concept allows study of pathogens using ONLY primary structure of their protein and DNA components. This unique feature of the MS-based bioinformatics approach allows analysis (e.g. host-pathogen interaction, assessment of biological effect of mutations, functional phylogenetic analysis, identification of therapeutic and vaccine targets, etc.) and characterization of new and emerging pathogens immediately after their isolation.

(i) first ever reported CD4 binding site of HIV-1 gp120 was published 1988 (article Veljkovic V. & Metlas R. Cancer Biochem Biophys. 1988;10:91 is among first 2% of 309901 HIV articles ever published (PubMed assessed on November 2016); (ii) analysis of mutations of pandemic pH1N1 influenza virus and identification of the candidate vaccine determinant was published during the first month of 2009 pandemic (article Veljkovic et al. BMC Struct, Biol. 2009;9:62 was submitted in June 2009); (iii) analysis of host-Ebola virus interaction and identification of candidate therapeutic target were published during the first month of the Ebola 2015 outbreak in West Africa (article Veljkovic et al. Front. Microbiol. 2015;9:6 was submitted in January 2015); candidate vaccine for Zika virus was proposed in the first month of the large outbreak in Brazil (article Veljkovic et al. F1000Research 2016;4:104 was published in May 2016).

The MS-based bioinformatics tool also is useful in early identification of candidate pandemic/epidemic pathogens (Perovic et al. PLOS One 2013;8:e61572, Veljkovic et al. PLOS One 2016;11;e165451) and selection of the conserved antigens for vaccines against highly variable pathogens Veljkovic et a. BMC Struct. Biol. 2009;9:21, Vergaras-Alert et al, PLOS One 2012;7:e40524). Molecular descriptors AQVN and EIIP served as a base for the general rule for selection of antibiotic combinations against multi-drug resistant bacteria (Veljkovic et al. Discoveries 2016;4:e64, doi:10,15190/d.2016.11).



The MS-based tool is useful for study of pathogenic molecular pathways associated with chronic diseases.

(i) analysis of interaction of antibodies induced with the influenza vaccine with bradykinin pathway opened possibility for development of vaccine against cardiovascular diseases (Veljkovic et al. Vaccine 2014;32:6569); (ii) the structure/function analysis of lipoprotein lipase performed with the MS-base tool allowed development of the criterion for assessment of mutations as the risk factor for cardiovascular diseases (Glisic et al. Proteins 2008;70:855); (iii) the MS concept was used for study of molecular mechanisms underlying pathophysiological processes of neurocardiovascular syndromes and discovery of therapeutics targets for their treatment (Bojic et al. Front. Neurosci. 2016;9:520); (vi) study of interaction between VIP receptors and natural anti-VIP antibodies served as a base for development of the prognostic ELISA test for breast and prostate cancer (Veljkovic et al. PLOS One 2011;6:e28304).

Our Tools

H3N2 Vaccine Efficacy

Our Products

Our Services

Drug repurposing

Screening of the drug space (drug databases) for approved drugs which are effective against new therapeutic targets.


Drug discovery

Development of filters for in silico screening of molecular libraries for drug candidates.


Functional phylogenetic analysis

Monitoring of evolution of pathogens toward increased pandemic/epidemic potential.


Vaccine development

Selection and de novo design of antigens for infectious and chronic diseases.


New therapeutic targets

Discovery of new therapeutic targets for infectious and chronic diseases.


Assessment of effect of mutations

Assessment of biological effect of two or more mutations in protein. It is ONLY available bioinformatics tool which allows assessment of the cumulative effect of mutations.


Protein structure/function analysis

Mapping of interacting domains of proteins.


Protein-protein interactions

Identification of protein interactors by screening of UniProt and GenBank databases.



Galveston, Texas 77550, USA